EP1246805A1 - Tetrahydroisoquinolines a substitution 4-phenyle et utilisation de ces dernieres pour bloquer le recaptage de la norepinephrine, de la dopamine et de la serotonine - Google Patents

Tetrahydroisoquinolines a substitution 4-phenyle et utilisation de ces dernieres pour bloquer le recaptage de la norepinephrine, de la dopamine et de la serotonine

Info

Publication number
EP1246805A1
EP1246805A1 EP00976884A EP00976884A EP1246805A1 EP 1246805 A1 EP1246805 A1 EP 1246805A1 EP 00976884 A EP00976884 A EP 00976884A EP 00976884 A EP00976884 A EP 00976884A EP 1246805 A1 EP1246805 A1 EP 1246805A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
tetrahydroisoquinoline
methyl
alkyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00976884A
Other languages
German (de)
English (en)
Inventor
James P. Beck
Mark A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMR Technology Inc
Original Assignee
Albany Molecular Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Research Inc filed Critical Albany Molecular Research Inc
Publication of EP1246805A1 publication Critical patent/EP1246805A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Definitions

  • the present invention relates to compounds, compositions, methods for the treatment of various neurological and psychological disorders, and the use of the compounds in combination therapy.
  • the present invention relates to such compounds, compositions and methods wherein the compounds are novel 4-phenyl substituted tetrahydroisoquinolines derivatives.
  • duloxetine and fluoxetine which are known serotonin reuptake inhibitors have been found to be useful in the treatment of depression, obesity and obsessive-compulsive disease (Wong, et al., U.S. Patent No. 5,532,244).
  • Moldt, et al., U.S. Patent No. 5,444,070 discloses the use of dopamine reuptake inhibitors in the treatment of depression, Parkinsonism, drug addiction and/or abuse, cocaine and/or amphetamine addiction and/or abuse. Fre ⁇ dman, et al., U.S. Patent No.
  • 6,136,803 also discloses synaptic norepinephrine or serotonin uptake inhibitors which are useful in treating depression in a patient.
  • Norden, U.S. Patent No. 5,789,449 discloses the use of serotonin re-uptake inhibitors in treating psychiatric symptoms consisting of anger, rejection sensitivity, and lack of mental or physical energy.
  • Foster, et al., U.S. Patent No. 4,902,710 discloses the use of serotonin and norepinephrine uptake inhibitors in suppressing the desire of humans to smoke or consume alcohol.
  • U.S. Patent No. 4.843,071 discloses the use of a norepinephrine re-uptake inhibitor and a norepinephrine precursor in the treatment of obesity, drag abuse, or narcolepsy in a patient.
  • Wong, et al., U.S. Patent No. 5,532,244 discloses the use of serotonin reuptake inhibitors in combination with a serotonin 1 A receptor antagonist, to increase the availability of serotonin, norepinephrine and dopamine in the brain.
  • the treatment of a va ⁇ ety of neurological and psychiatric disorders is characterized by a number of side effects believed to be due to the compounds' inability to selectvely block certain neurochemicals, and not others ADHD, for example, is a disease affecting 3-6% of school age children, and is also recognized in percentage of adults Aside from hampering performance at school, and at work, ADHD is a significant risk factor for the subsequent development of anxiety disorders, depression, conduct disorder and drug abuse Since current treatment regimes require psychostimulants, and since a substantial number of patients (30%) are resistant to stimulants or cannot tolerate their side effects, there is a need for a new drug or class of drugs which treats ADHD and does not have resistance or side effect problems In addition, methylphenidate, the current drug of choice for the treatment of ADHD, induces a number of side effects, these include anorexia, insomnia and jittery feelings, tics, as well as increased blood pressure and heart rate secondary to the activation of the sympathetic nervous system However, Methylphenidate also has a high selectivity
  • Nomofensine® which is a 4 phenyl-substituted tetrahydroisoquinoline derivative is known to inhibit the neuronal uptake of dopamine and other catecholamines and has shown clinical efficacy for ADHD
  • long term administration of Nomofensine® results in fatal immune hemolytic anemia
  • novel compounds which treat ADHD but do not have the serious side effects associated with Nomifensine® or the currently prescribed psychostimulants
  • the present invention discloses novel aryl and heteroaryl substituted tetrahydroisoquinoline derivatives compounds which block reuptake of norephineDhnne dopamine or serotonin, and are usefu* as alternatives to methylphenidate, and known psychostimulants, in the treatment of ADHD and other neurological and psychiatric disorders.
  • the claimed compounds which block reuptake of norephinephrine, dopamine, and serotonin with particular selectivity ratios, e.g., being more selective for the norepinephrine transporter (NET) protein than dopamine transporter (DAT) protein or serotonin transporter (SERT) protein (lower Ki for NET than for DAT and SERT). It is postulated that the compounds would therefore be effective as an ADHD treatment with reduced addictive liability profiles. In particular, some of the compounds of this invention are surprisingly and particularly selective for NET over the SERT protein, thus also affording compounds without the known side effect profiles of the selective serotonin reuptake inhibitor (SSRI) class of compounds.
  • SSRI selective serotonin reuptake inhibitor
  • R' is C r C 6 alkyl, C 2 -C Training alkenyl, C 2 -C 6 alkynyl, C,-C ⁇ cycloalkyl or C 4 -C 7 cycloalkylalkyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence thereof from C.-C, alkyl, halogen, aryl, -CN, -OR 9 and -NR 9 R"';
  • R 2 is H, C,-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C,-C 6 cycloalkyl, C 4 -C 7 cycloalkylalkyl or C,-C ft haloalkyl;
  • R 1 is H, halogen, -OR 11 , -S(O) R0 -S(O) NR"R0 -CN, -C(O)R0 -C(O)NR"R0 C,-C ⁇ alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C,-C cycloalkyl, C 4 -C 7 cycloalkylalkyl, -O(phenyl) or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl, or C,-C 4 alkoxy, or wherein R' is a C,-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkyny
  • R 1 is -O(phenyl), -O(benzyl), -OC(0)R ⁇ or -S(O) n R0 each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl, or C,-C alkoxy;
  • R 4 is H. halogen, -OR", -S(O) R0 -S(O)NR"R0 -CN, -C(O)R0 -C(O)NR"R0 - NR"R0 C,-C 6 alkyl, C,-C f ⁇ alkenyl, C,-C f alkynyl, C,-C e cycloalkyl, C 4 -C 7 cycloalkylalkyl, -O(phenyl) or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C ⁇ C ⁇ alkyl, C,-C 4 haloalkyl, or C,-C 4 alkoxy and wherein R 4 is a C C alkyl, C 2 -C 6 alkenyl, C,-C ⁇ alkyn
  • R 4 is -O(phenyl), -O(benzyl), -OC(O)R0 -NR"R 12 or - S(O) n R0 each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C alkyl, C,-C 4 haloalkyl. or C,-C 4 alkoxy;
  • R ⁇ R'' and R' in compounds of each of the formulae IA, IB, IC, ID. IE and IF are each independently H. halogen, -OR0 -S(O) R0 -CN, -C(O)R0 -NR"R0 -C(O)NR"R0 -NR"C(O)R0 -NR"C(O ⁇ R0 - NR"C(O)NR I2 R0 C,-C f alkyl, C 2 -C 6 alkenyl, C,-C fi alkynyl, C,-C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, wherein each of R ⁇ R" and R 7 is a C,-C 6 alkyl, C,-C ⁇ alkenyl, C,-C f ⁇ alkynyl, C,-C 6 cycloalkyl or C 4 -C, cycloalkylalkyl group, then said group
  • -OR 9 and -NR R"', or R' and R" or R 6 and R 7 may be -0-C(R 12 ) -0-; provided that for compounds of formula IE at least one of R " or R is fluoro, chloro, or methyl: or R' and R 6 are each independently -0-C(R 12 ),-0- in compounds of the formulae IE, but only where R 7 is fluoro, chloro or methyl; or R 7 and R 6 can independently also be -0-C(R l2 ),-0- in compounds of the formulae IE, but only where
  • R ⁇ is fluoro, chloro or methyl
  • R 8 is H, halogen, or OR", provided that for compounds of formula IF, R * is halogen;
  • R 9 and R 1 " are each independently H, C,-C 4 alkyl, C,-C 4 haloalkyl, C,-C alkoxyalkyl, C.-C ⁇ cycloalkyl,
  • R 9 and R 1 " are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, mo ⁇ holine, or thiomo ⁇ holine;
  • R" is H, C,-C 4 alkyl, C,-C 4 haloalkyl, C,-C 4 alkoxyalkyl, C C 6 cycloalkyl, C 4 -C 7 cycloalkylalkyl, -
  • R' 2 is H, amino, C,-C 4 alkyl, (C,-C alkyl)amino, C,-C 4 haloalkyl, C,-C alkoxyalkyl, C,-C 6 cycloalkyl, C 4 -
  • R ⁇ is C,-C alkyl, C,-C haloalkyl or phenyl; n is 0, 1, or 2, and; aryl is phenyl which is optionally substituted 1 -3 times with halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl and C,-C 4 alkoxy, or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or prodrug thereof.
  • Alkyl means an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, ⁇ -propyl, z-propyl, n-butyl, t-butyl, «-pentyl, and 3-pentyl.
  • alkenyl means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkenyl chain. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, and -butenyl.
  • Alkynyl means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkynyl chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, and n-pentynyl.
  • Aryl means an aromatic monocyclic or multicyclic ring system of 6 to about 14 carbon atoms, preferably of 6 to about 10 carbon atoms. Representative aryl groups include phenyl and naphthyl.
  • Heteroaryl means an aromatic monocyclic or multicyclic ring system of about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is/are element(s) other than carbon, for example, nitrogen, oxygen or sulfur.
  • Preferred heteroaryls contain about 5 to 6 ring atoms.
  • aza, oxa or thia before heteroaryl means that at least a nitrogen, oxygen or sulfur atom, respectively, is present as a ring atom.
  • a nitrogen atom of a heteroaryl is optionally oxidized to the corresponding N-oxide.
  • heteroaryls include pyrazinyl; furanyl: thienyl; pyridyl; pyrimidinyl; isoxazolyl; isothiazolyl; oxazolyl; thiazolyl; pyrazolyl; furazanyl; pyrrolyl; pyrazolyl; triazolyl; 1 ,2,4-thiadiazolyl; pyrazinyl; pyridazinyl; quinoxalinyl; phthalazinyl; l(2H)-phthalazinonyl; imidazo[l ,2-a]pyridine; imidazo[2, l -b]thiazolyl; benzo furazanyl; indolyl: azaindolyl; benzimidazolyl; benzothienyl; quinolinyl: imidazolyl; thienopyridyl; quinazolinyl; thienopyrimidyl;
  • Alkoxy means an alkyl-O- group wherein the alkyl group is as herein described.
  • Exemplary alkoxy groups include methoxy, ethoxy, /7-propoxy, -propoxy. «-butoxy and heptoxy.
  • Compounds of the invention are meant to embrace compounds of general formulae (IA-F) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits.
  • reference to intermediates, whether or not they themselves are claimed is meant to embrace their salts, and solvates, where the context so permits.
  • particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.
  • Cycloalkyl means a non-aromatic mono- or multicyclic ring system of about 3 to about 7 carbon atoms, preferably of about 5 to about 7 carbon atoms.
  • Exemplary monocyclic cycloalkyl include cyclopentyl, cyclohexyl, cycloheptyl, and the like.
  • Cycloalkylalkyl means an cycloalkyl-alkyl- group in which the cycloalkyl and alkyl are as defined herein.
  • Exemplary cycloalkylalkyl groups include cyclopropylmethyl and cy clopenty lmethy 1.
  • Halo or "halogen” means fluoro, chloro, bromo, or iodo.
  • Haloalkyl means both branched and straight-chain alkyl substituted with 1 or more halogen, wherein the alkyl group is as herein described.
  • Haloalkoxy means a C alkoxy group substituted by at least one halogen atom, wherein the alkoxy group is as herein described.
  • “Pharmaceutically acceptable salts” means the relatively non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds.
  • acid addition salts can be prepared by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
  • Exemplary acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate. stearate, laurate, borate. benzoate, lactate, phosphate, tosylate.
  • Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed
  • Base addition salts include pharmaceutically acceptable metal and amine salts
  • Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum salts
  • the sodium and potassium salts are preferred
  • Suitable inorganic base addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide
  • Suitable amine base addition salts are prepared from amines which have sufficient basicity to form a stable salt, and preferably include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithme, choline, N,N'-d
  • dehydroabietylamine N- ethylpipe ⁇ dine, benzylamme, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e g , lysine and arginine, and dicyclohexylamme, and the like
  • prodrugs as used herein means those prodrugs of the compounds useful according to the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitte ⁇ onic forms, where possible, of the compounds of the invention
  • prodrug' means compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hvdrolysis in blood
  • Functional groups which may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group of the compounds of this invention They include, but are not limited to such groups as alkanoyl (such as acetyl, propionyl, butyryl.
  • the compounds bearing such groups act as pro-drugs
  • the compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of abso ⁇ tion conferred upon the parent compound by virtue of the presence of the metabolically cleavable group
  • prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention.
  • the term "Therapeutically effective amounts” is meant to describe an amount of compound of the present invention effective in increasing the levels of serotonin, norepinephrine or dopamine at the synapse and thus producing the desired therapeutic effect. Such amounts generally vary according to a number of factors well within the purview of ordinarily skilled artisans given the description provided herein to determine and account for. These include, without limitation: the particular subject, as well as its age, weight, height, general physical condition and medical history; the particular compound used, as well as the carrier in which it is formulated and the route of administration selected for it; and, the nature and severity of the condition being treated.
  • composition means a composition comprising a compound of formulae (IA-F) and at least one component selected from the group comprising pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.
  • pharmaceutically acceptable carriers such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.
  • suspending agents examples include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances.
  • Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol. phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged abso ⁇ tion of the injectable pharmaceutical form can be brought about by the use of agents delaying abso ⁇ tion, for example, aluminum monosterate and gelatin.
  • suitable carriers, diluents, solvents or vehicles include water, ethanol, polyols, suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • excipients include lactose, milk sugar, sodium citrate, calcium carbonate, dicalcium phosphate phosphate.
  • disintegrating agents include starch, alginic acids and certain complex silicates.
  • lubricants include magnesium stearate, sodium lauryl sulphate, talc, as well as high molecular weight polyethylene glycols.
  • “Pharmaceutically acceptable” means it is, within the scope of sound medical judgement, suitable for use in contact with the cells of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable dosage forms” means dosage forms of the compound of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, solutions, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.
  • Another embodiment of the invention is a compound of formulae IA-IF wherein: the carbon atom designated * is in the R or S configuration.
  • Another embodiment of the invention is a compound of formulae IA. IB, IC, ID, IE and IF, wherein:
  • R' is C,-C 6 alkyl, C,-C 6 alkenyl, C,-C 6 alkynyl, C,- ⁇ cycloalkyl or C 4 -C 7 cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C,-C, alkyl, halogen, aryl. -CN, -OR 9 and -NR R'".
  • Another embodiment of the invention is a compound of formulae IA, IB, IC, ID, IE and IF, wherein:
  • R 2 is H, C,-C 6 alkyl, C,-C 6 alkenyl, C,-C 6 alkynyl, C,-C 6 cycloalkyl, C 4 -C 7 cycloalkylalkyl or C,- C f ⁇ haloalkyl.
  • Another embodiment of the invention is a compound of formulae IA, wherein: R 1 as C,-C 6 alkyl. C,-C alkenyl, C,-C 6 alkynyl, C,-C 6 cycloalkyl or C -C 7 cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C,-C, alkyl, halogen, aryl, -CN, -OR 9 and -NR 9 R"'.
  • Another embodiment of the invention is a compound of formulae IB, wherein: R' as -O(phenyl), -O(benzyl), -OC(O)R" or -S(O) R0 each of -O( ⁇ henyl) and -O(benzyl) optionally substituted with 1 to 3 substituents selected independently at each occurrence thereof from halogen, cyano, C,-C alkyl, C,-C haloalkyl or C,-C alkoxy.
  • R 1 is H, halogen, -OR", -S(O) R 12 , -S(O)NR"R0 -CN, -C(O)R0 -C(O)NR"R0 -O(phenyl), - O(benzyl), -OC(0)R” or -S(O) R0 C,-C 6 alkyl, C 2 -C fi alkenyl, C,-C fi alkynyl, C,-C 6 cycloalkyl and C 4 -C 7 cycloalkylalkyl, wherein each of C,-C ( ⁇ alkyl, C,-C alkenyl.
  • C,-C n alkynyl, C,-C 6 cycloalkyl and C -C cycloalkylalkyl is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from 0,-C, alkyl, halogen, aryl, -CN, -OR 9 and -NR 9 R0 and wherein R 1 is a - O(phenyl) or -O(benzyl) group, then said group is optionally substituted with 1 to 3 substituents selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl or C,-C 4 alkoxy.
  • Another embodiment of the invention is a compound of formula IC, wherein: R 4 is C,-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C,-C ⁇ cycloalkyl, or C 4 -C 7 cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C,-C, alkyl, halogen, aryl, -CN, -OR" and -NR 9 R'".
  • Another embodiment of the invention is a compound of formula ID, wherein:
  • R 4 is -O(phenyl), -O(benzyl), -OC(O)R0 -NR"R 12 or -S(O) R0 and said -O(phenyl) or - O(benzyl) is optionally substituted with 1 to 3 substituents selected independently at each occurrence thereof from halogen, cyano, C,-C alkyl, C,-C 4 haloalkyl and C,-C 4 alkoxy.
  • R 4 is H, halogen, -OR", -S(O) R 12 , -S(O)NR"R0 -CN, -O(phenyl), -O(benzyl), -OC(O)R0 -
  • R ⁇ R" and R 1 are each independently H. halogen, -OR", -S(O) R0 -CN, -C(O)R0 -NR"R0 - C(O)NR"R0 -NR"C(O)R0 -NR"C(O) R0 -NR"C(O)NR I2 R0 C,-C 6 alkyl, C 2 -C ⁇ alkenyl, C,-C f alkynyl, C ⁇ C,.
  • each R ⁇ R" and R 7 is independently a C,-C f alkyl, C 2 - C 6 alkenyl, C,-C f alkynyl, C 1 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl group, then said group is optionally substituted from 1 to 3 times with substituents selected independently at each occurrence thereof from C,-C, alkyl, halogen, aryl, -CN, -OR u and -NR 9 R IU , or R ⁇ and R" or R 6 and R 7 may be -0-C(R' 2 ) 2 -0-.
  • R s is fluoro, chloro. or methyl; then R' and R" are each independently H, halogen, -OR", - S(O) R0 -CN, -C(O)R0 -NR"R 12 , -C(0)NR"R 12 , -NR"C(0)R 12 , -NR n C(O) 2 R0 -NR"C(O)NR I2 R0 C,-C alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C,-C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, wherein each of R and R" are a C,-C 6 alkyl, C 2 -C 6 alkenyl, C -C 6 alkynyl, C,-C 6 cycloalkyl orC 4 -C 7 cycloalkylalkyl group,
  • Another embodiment of the invention is a compound of formula IE, wherein:
  • R 7 is fluoro, chloro or methyl, then R' and R 6 together can also be -0-C(R 12 ) 2 -0-.
  • Another embodiment of the invention is a compound of formula IE, wherein:
  • R' is fluoro, chloro or methyl, then R 7 and R 6 together can also be -0-C(R 12 ) 2 -0-.
  • Another embodiment of the invention is a compound of formulae LA-IE, wherein:
  • R 8 is H, halogen, or OR.
  • Another embodiment of the invention is a compound of formula IF, wherein R 8 is halogen.
  • Another embodiment of the invention is a compound of formulae IA-F, wherein:
  • R 9 and R 1 " are each independently H, C,-C 4 alkyl, C,-C 4 haloalkyl, C,-C 4 alkoxyalkyl, C,-C 6 cycloalkyl, C 4 -C 7 cycloalkylalkyl, -C(O)R0 phenyl or benzyl, where said phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl, or C,-C 4 alkoxy; or
  • R 9 and R l() are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, mo ⁇ holine, or thiomo ⁇ holine rings.
  • Another embodiment of the invention is a compound of formulae IA-F, wherein:
  • R" is H, C,-C 4 alkyl, C,-C 4 haloalkyl, C,-C 4 alkoxyalkyl, C,-C 6 cycloalkyl, C 4 -C 7 cycloalkylalkyl, -C(O)R0 phenyl or benzyl, where said phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C alkyl, C,-C 4 haloalkyl, or C,-C 4 alkoxy.
  • Another embodiment of the invention is a compound of formulae IA-F, wherein:
  • R' 2 is H, C,-C 4 alkyl, C,-C 4 haloalkyl, C,-C 4 alkoxyalkyl, C,-C 6 cycloalkyl, C 4 -C 7 cycloalkylalkyl, phenyl or benzyl, where said phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl and C,-C alkoxy; or
  • R" and R 12 are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine. N-methylpiperazine, mo ⁇ holine or thiomo ⁇ holine rings.
  • Another embodiment of the invention is a compound of formulae IA-F, wherein:
  • R ⁇ is C,-C 4 alkyl, C,-C 4 haloalkyl or phenyl; and n is 0, 1 , or 2.
  • Preferred embodiments of this invention are compounds of fomullae LA-IF, wherein:
  • R' is C,-C, alkyl
  • R 2 is H, C,-C 4 alkyl or C,-C complicat haloalkyl.
  • Preferred embodiments of this invention are compounds of formulae IA, IC, ID, IE and IF, wherein:
  • R' is C,-C 4 alkyl, C,-C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each of these groups being optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C,-C, alkyl. halogen, aryl, -CN, -OR 9 and -NR 9 R'°.
  • Preferred embodiments of this invention are compounds of formula IB, wherein:
  • R 1 is -O(phenyl) or -O(benzyl), is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl, or C,-C 4 alkoxy.
  • Preferred embodiments of this invention are compounds of formulae IC, ID, IE and IF: wherein R 1 is -O(phenyl) or -O(benzyl), and is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl, and C,-C alkoxy.
  • Preferred embodiments of this invention are compounds of formulae IC-IF, wherein: R' is H.
  • Preferred embodiments of this invention are compounds of formulae IA, IB, IC, IE and IF, wherein:
  • R 4 is C,-C 4 alkyl, C,-C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each of these groups being optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from 0,-C, alkyl, halogen, aryl, -CN, -OR 9 and -NR*R'".
  • Preferred embodiments of this invention are compounds of formulae IA, IB, IE and IF, wherein:
  • R 4 is H.
  • Preferred embodiments of this invention are compounds of formulae IA, IB, IE and IF, wherein:
  • R 4 is -NR"R0 -O(phenyl) or -O(benzyl), each of these aryl groups being is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl, or C,-C 4 alkoxy.
  • Preferred embodiments of this invention are compounds of formulae IE and IF, wherein:
  • R ' and R 4 are both halogen.
  • Preferred embodiments of this invention are compounds of formulae IA, IB, IC, ID and IF, wherein:
  • R ⁇ R" and R 7 are each H, halogen, -OR", -NR"R0 C,-C ⁇ alkyl or C,-C 6 alkyl optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C,-C, alkyl, halogen, aryl, -CN, -OR 9 and -NR R'".
  • Preferred embodiments of this invention are compounds of formulae IA, IB, IC, ID, IE and IF, wherein: R s is fluoro, chloro or methyl; one of R 6 or R 7 is H; and the other of R 6 or R 7 which is not H is halogen, -OR", -NR H R 12 , C,-C 6 alkyl or C I -C 6 alkyl each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C,-C, alkyl, halogen, aryl, -CN, -OR 9 and - NR 9 R0
  • Preferred embodiments of this invention are compounds of formulae IA, IB, IC, ID and IE, wherein:
  • R 8 is H or halogen.
  • Preferred embodiments of this invention are compounds of formula IF, wherein: R 8 is halogen.
  • Preferred embodiments of this invention are compounds of formulae IA, IB, IC, ID, IE and IF, wherein: the substituents R'-R 8 are as set forth in the following table B:
  • More preferred embodiments of this invention are compounds wherein: R 1 is C r C, alkyl; R 2 is H or C,-C, alkyl;
  • R' is H, C,-C 4 alkyl, -O(phenyl) or optionally substituted -O(phenyl), more preferably halogen
  • R 4 is H, C,-C 4 alkyl, -O(phenyl) or optionally substituted -O(phenyl), more preferably halogen
  • R s is F, Cl or Me, more preferably -OR", wherein R" is C,-C, alkyl; R 6 is H or more preferably Cl, F, C,-C, alkyl, halo-substituted C,-C, alkyl, or -OR", R" is C,-C, alkyl or -NR"R 12 ;
  • R 7 is H or more preferably Cl, F, C,-C, alkyl or -OR", wherein R" is C,-C, alkyl.
  • a further more preferred embodiments of this invention are compounds wherein:
  • R' is CH,; R 2 is H or CH,;
  • R 1 is H, CH,, or -O(phenyl) or -0-CH 2 -(phenyl), each of said -O(phenyl) or -0-CH 2 -(phenyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl, or C,-C 4 alkoxy;
  • R 4 is H, F, CHfind CH 2 CH,, CH 2 CH 2 CHiff CH 2 CH(CH,)CHinstitut -O(phenyl) or -0-CH 2 -phenyl, where each of said -O(phenyl) or -0-CH,-(phenyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C,-C 4 alkyl, C,-C 4 haloalkyl, or C,-C 4 alkoxy; R0s H, CH,, OCHfix F or Cl ;
  • R" is H, CHvisor -OCH fashion F, Cl or CF,; R 7 is H, F, Cl. CH, or OCH,; and R 8 is halogen.
  • the specifically preferred compounds are:
  • Another preferred aspect of the invention is a mixture of compounds of formulae (IA-F) wherein the compound of formulae (IA-F) is radiolabeled, i.e., wherein one or more of the atoms described are replaced by a radioactive isotope of that atom (e.g , C replaced by l C and H replaced by 3 H).
  • radiolabeled i.e., wherein one or more of the atoms described are replaced by a radioactive isotope of that atom (e.g , C replaced by l C and H replaced by 3 H).
  • Such compounds have a variety of potential uses, e.g., as standards and reagents in determining the ability of a potential pharmaceutical to bind to neurotransmitter proteins.
  • Another aspect of the invention is a therapeutically effective amount of the compound of formulae (IA-F) and a pharmaceutically acceptable carrier.
  • Another aspect of the invention is a method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formulae (IA-F), or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formulae (IA-F), or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a serotonin 1 A receptor antagonist, or pharmaceutically acceptable salt thereof.
  • a compound of formulae (IA-F) or a pharmaceutically acceptable salt thereof
  • a serotonin 1 A receptor antagonist or pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formulae (IA-F), or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a compound selected from the group consisting of WAY 100135 and spiperone, or pharmaceutically acceptable salt thereof.
  • WAY 100135 N-(t-butyl)-3-[a-(2-methoxyphenyl)piperazin-l-yl]-2-phenylpropanamide
  • Spiperone (8-[4-(4-fluorophenyl)-4-oxobutyl]- l -phenyl- 1 , 3, 8-triazaspiro[4,5]decan-4- one) is a well- known compound, and is diclosed in U.S. Pat. Nos. 3, 155,669 and 3,155,670.
  • the activity of Spiperone as a 5-HT 1 ⁇ antagonist is shown in Middlemiss et al., Neurosci. and Biobehav. Rev.
  • Another aspect of the invention is a method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formulae (IA-F) , or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a selective neurokinin- 1 receptor antagonist, or pharmaceutically acceptable salt thereof.
  • a compound of formulae (IA-F) or a pharmaceutically acceptable salt thereof
  • a selective neurokinin- 1 receptor antagonist or pharmaceutically acceptable salt thereof.
  • Neurokinin-1 receptor antagonists of use in combination a compound of formulae (IA-F) in the present invention are fully described, for example, in U.S. Pat. Nos. 5,373,003, 5,387,595, 5,459,270, 5,494,926, 5,162,339, 5,232,929, 5,242,930, 5,496,833, 5,637,699; PCT International Patent Publication Nos. WO 90/05525, 90/05729, 94/02461 , 94/02595, 94/03429,94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/08997. 94/10165. 94/10167.
  • Another aspect of the invention is a method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formulae (IA-F) , or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a norepinephrine precursor, or pharmaceutically acceptable salt thereof.
  • a method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formulae (IA-F) , or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a norepinephrine precursor, or pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formulae (IA-F) , or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a compound selected from L-tyrosine and L-phenylalanine, or pharmaceutically acceptable salt thereof.
  • a compound of formulae (IA-F) or a pharmaceutically acceptable salt thereof
  • a compound selected from L-tyrosine and L-phenylalanine or pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a method of treating a disorder referred to in the above- mentioned embodiments, wherein the disorder is selected from the group: attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, panic attacks, Parkinsonism and phobia, obesity, late luteal phase syndrome or narcolepsy, cocaine addiction, amphetamine addiction, and psychiatric symptoms anger such as, rejection sensitivity, and lack of mental or physical energy.
  • Another aspect of the invention is a method of inhibiting synaptic norepineph ⁇ ne uptake in a patient in need thereof comp ⁇ sing administering a therapeutically effective inhibitory amount of a compound of formulae (IA-F)
  • Another aspect of the invention is a method of inhibiting synaptic serotonin uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound of formulae (IA-F)
  • Another aspect of the invention is a method of inhibiting synaptic dopamine uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound of formulae (IA-F)
  • Another aspect of the invention is a therapeutic method described herein wherein the (+)- stereoisomer of the compound of formulae (IA-F) is employed
  • Another aspect of the invention is a therapeutic method described herein wherein the (-)- stereoisomer of the compound of formulae (IA-F) is employed
  • kits comprising a compound of formulae (IA-F) and at least one compound selected from the group consisting of a serotonin 1 A receptor antagonist compound, a selective neurok ⁇ n ⁇ n-1 receptor antagonist compound, and a norepinephrine precursor compound
  • Another aspect of the invention is a method of treating depression in a patient in need thereof comprising inhibiting synaptic serotonin and norepinephrine uptake by administering a therapeutically effective inhibitory amount of a compound of formulae (IA-F) which functions as both a serotonin and norepinephrine uptake inhibitor
  • Another aspect of the invention is a method of treating depression in a patient in need thereof comprising inhibiting synaptic serotonin and dopamine uptake by administering a therapeutically effective inhibitory amount of a compound of formulae (IA-F) which functions as both a serotonin and dopamine uptake inhibitor
  • Another aspect of the invention is a method of treating depression in a patient in need thereof comprising inhibiting synaptic dopamine and norepinephrine uptake by administering a therapeutically effective inhibitory amount of a compound of formulae (IA-F) which functions as both a dopamine and norepinephrine uptake inhibitor
  • Another aspect of the invention is a method for inhibiting serotonin uptake in mammals which comprises administering to a mammal requiring increased neurotransmission of serotonin a pharmaceutically effective amount of a compound of formulae (IA-F)
  • Another aspect of the invention is a method for inhibiting dopamine uptake in patients which comprises administering to a mammal requiring increased neurotransmission of dopamine a pharmaceutically effective amount of a compound of formulae (IA-F)
  • Another aspect of the invention is a method for inhibiting norepinephrine uptake in patients which comprises administering to a mammal requiring increased neurotransmission of norepinephrine a pharmaceutically effective amount of a compound of formulae (IA-F) .
  • Another aspect of the invention is a method of suppressing the desire of humans to smoke comprising administering to a human in need of such suppression an effective dose, to relieve the desire to smoke, of a compound of formulae (IA-F) .
  • Another aspect of the invention is a method of suppressing the desire of humans to consume alcohol comprising administering to a human in need of such suppression an effective dose, to relieve the desire to consume alcohol, of a compound of formulae (IA-F) .
  • certain feactures of the invention which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment.
  • various feactures of the invention which are, for brevity, described in the context of a single embodiment, may also be provided seperately or in any suitable subcombination.
  • a compound of formulae (IA-F) including a group containing one or more nitrogen ring atoms may be converted to the corresponding compound wherein one or more nitrogen ring atom of the group is oxidized to an N-oxide, preferably by reacting with a peracid, for example peracetic acid in acetic acid or m-chloroperoxybenzoic acid in an inert solvent such as dichloromethane, at a temperature from about room temperature to reflux, preferably at elevated temperature.
  • a peracid for example peracetic acid in acetic acid or m-chloroperoxybenzoic acid in an inert solvent such as dichloromethane
  • NHR 1 cleanly generates the alkylation products of formula (V)
  • the alkylation reactions may be run under a wide variety of conditions familiar to one skilled in the art of organic synthesis Typical solvents include acetonit ⁇ le, toluene, diethyl ether, tetrahydrofuran, dimethylsulfoxide, dimethylformamide, methylene chloride, and lower alkyl alcohols including ethanol
  • the reactions may be successfully run at temperatures ranging from 0°C up to the boiling point of the solvent employed Reaction progress is conventionally determined by standard chromatographic and spectroscopic methods
  • the alkylation reaction is optionally run with the addition of a non-nucleophihc organic base such as, but not limited to, py ⁇ dine, triethylamine and dnsopropyl ethylamine
  • the R0substituted N-benzyl amines of formula (R 3 ,R 4 -Ph)-CH(R 2 )-NHR 1 may be purchased from commercial sources, or alternatively, obtained from a simple reductive animation protocol
  • carbonyl containing compounds of Formulae (IV, Scheme 1 ) may be treated with H2N-R 1 in lower alkyl alcoholic solvents (preferably methanol) at temperatures at or below room temperature
  • the resulting imme may be reduced most commonly with alkaline earth borohydrides (preferably sodium borohydride) to provide the desired amine intermediate
  • Reductions of compounds of formula (V) to the benzyl alcohols of formula (VI) proceeds with many reducing agents including, as example, sodium borohydride, lithium borohydride, borane, diisobutylaluminum hvd ⁇ de. and lithium aluminum hydride
  • the reductions are carried out for a period of time between 1 hour to 3 days at room temperature or elevated temperature up to the reflux point of the solvent employed.
  • borane it may be employed as a complex for example, but not limited to, borane-methyl sulfide complex, borane-piperidine complex, borane-tetrahydrofuran complex.
  • Compounds of formula (VI) may be cyclized to the target compounds of formulae LA-IF of this invention by brief treatment with a strong acid.
  • Suitable acids include, but are not limited to, concentrated sulfuric acid, polyphosphoric acid, methanesulfonic acid and trifluoroacetic acid.
  • the reactions are run neat or in the optional presence of a co-solvent such as, for example, methylene chloride and 1 ,2-dichloroethane.
  • the cyclizations may be conducted at temperatures ranging from 0°C up to the reflux point of the solvent employed.
  • a co-solvent such as, for example, methylene chloride and 1 ,2-dichloroethane.
  • the cyclizations may be conducted at temperatures ranging from 0°C up to the reflux point of the solvent employed.
  • One skilled in the art of heterocyclic chemistry will readily understand these conditions or may consult the teachings of Mondeshka, et al.
  • Cyclizations may also be effected by treatment of compounds of formula (VI) with strong Lewis Acids, such as for example, aluminum trichloride typically in halogenated solvents such as methylene chloride.
  • strong Lewis Acids such as for example, aluminum trichloride typically in halogenated solvents such as methylene chloride.
  • haloacetophenones of formula may be treated with simple amines of formula H2N-R 1 under alkylation conditions as described above (vide supra) to provide compounds of formulae (VII).
  • a second alkylation may then be performed utilizing reagents of formula (VIII) where X represents a leaving group, such as for example, but not limited to, halogen, mesylate, or tosylate to afford the common intermediate of formula (V).
  • Reagents of formula (VIII) are in turn available from the appropriately substituted carbonyl compound of formula (IV) via reduction (vide supra) and activation.
  • Activation to leaving group X is effected by treatment of the alcohol with methanesulfonyl chloride or /j-toluenesulfonyl chloride in the presence of a non-nucleophilic base such as, but not limited to, l,5-diazabicyclo[4.3.0]non-5-ene (DBN), pyridine or triethylamine.
  • a non-nucleophilic base such as, but not limited to, l,5-diazabicyclo[4.3.0]non-5-ene (DBN), pyridine or triethylamine.
  • DBN l,5-diazabicyclo[4.3.0]non-5-ene
  • pyridine pyridine
  • triethylamine triethylamine
  • Benzylic activation to Leaving Group X may also be effected by treatment with halogenating agents such as, but not limited to, SOoCb, CI2, PCI5, Br2, CuBr2, NBS, and CBr
  • halogenating agents such as, but not limited to, SOoCb, CI2, PCI5, Br2, CuBr2, NBS, and CBr
  • Compounds of formula (XI) may be treated with strong bases, such as, but not limited to lower alkyl ⁇ C ⁇ _ ) lithium bases (preferably t-BuLi or n-BuLi) to afford the anticipated halogen-metal exchange followed by intramolecular Barbier cyclization to generate compounds of formulae (IA-IE,
  • strong bases such as, but not limited to lower alkyl ⁇ C ⁇ _ ) lithium bases (preferably t-BuLi or n-BuLi) to afford the anticipated halogen-metal exchange followed by intramolecular Barbier cyclization to generate compounds of formulae (IA-IE,
  • R8 0H).
  • Inert solvents such as dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1 ,4-dioxane). etc. are necessary, and reaction temperatures are kept low (-78°C to - 25°C) to avoid by-products.
  • halogen-metal exchange may also be effected in the presence of zerovalent nickel, in which case N,N-dialkylformamides (preferably dimethylformamide) serve as ideal solvents.
  • Kihara, et al. Tetrahedron, 1992, 48.
  • Bromoisoquinolines (XII) may be treated with an aryl boronic acid or aryl boronic acid ester where Y is equivalent to B(OHb or B(OR a )(OR' 3 ) (where R a and R* 0 are lower alkyl, ie. Ci -C ⁇ . or taken together, R a and R D are lower alkylene. ie. C2-C12) in the presence of a metal catalyst with or without a base in an inert solvent to give isoquinoline compounds of formula (XIII).
  • Metal catalysts include, but are not limited to, salts or phosphine complexes of Cu, Pd, or Ni (eg.
  • Bases may include, but are not limited to, alkaline earth metal carbonates, alkaline earth metal bicarbonates, alkaline earth metal hydroxides, alkali metal carbonates, alkali metal bicarbonates, alkali metal hydroxides, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium diisopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably diisopropylethylamine or triethylamine) or aromatic amines (preferably pyridine).
  • alkaline earth metal carbonates alkaline earth metal bicarbonates, alkaline earth metal hydroxides, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (preferably sodium methoxide or sodium e
  • Inert solvents may include, but are not limited to acetonitrile, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1 ,4-dioxane), N,N- dialkylacetamides (preferably dimethylacetamide), N,N-dialkylformamides (preferably dimethylformamide), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloaalkanes (preferably methylene chloride).
  • Prefered reaction temperatures range from room temperature up to the boiling point of the solvent employed. The reactions may be run in conventional glassware or in one of many commercially available parallel synthesizer units.
  • Non-commercially available boronic acids or boronic acid esters may be obtained from the corresponding optionally substituted aryl halide as described by Gao, et al. (Tetrahedron, 1994, 50, 979-9
  • the second step of the sequence involves reduction to the tetrahydroisoquinolines of formulae IA-F.
  • a mild reducing agent is employed, such as for example, sodium cyanoborohydride in the presence of acid catalyst to facilitate the reaction. Additional guidance for effectively conducting this chemistry may be located from the works of Miller, et al. (Synthetic Communications. 1994, 24, 1 187-1 193) and Terashi a. et al. (Heterocycles, 1987, 26. 1603-1610).
  • compounds useful according to the present invention may contain asymmetric centres. These asymmetric centres may independently be in either the R or S configuration and such compounds are able to rotate a plane of polarized light in a polarimeter. If said plane of polarized light is caused by the compound to rotate in a counterclockwise direction, the compound is said to be the (-) stereoisomer of the compound. If said plane of polarized light is caused by the compound to rotate in a clockwise direction, the compound is said to be the (+) stereoisomer of the compound.
  • compositions containing the compounds described herein including, in particular, pharmaceutical compositions comprising therapeutically effective amounts of the compounds and pharmaceutically acceptable carriers
  • kits having a plurality of active ingredients (with or without carrier) which, together, may be effectively utilized for carrying out the novel combination therapies of the invention
  • kits or single packages combining two or more active ingredients useful in treating a disorder described herein
  • a kit may provide (alone or in combination with a pharmaceutically acceptable diluent or carrier), the compound of formulae (IA-F) and the additional active ingredient (alone or in combination with diluent or carrier) selected from a serotonin 1 A receptor antagonist, a selective neurok ⁇ n ⁇ n-1 receptor antagonist, and a norepinephrine precursor
  • compounds of the present invention may generally be administered parenterally. intravenously, subcutaneously intramuscularly, colonically, nasally, intraperitoneally, rectally or orally
  • compositions containing at least one product according to the invention which are suitable for use in human or veterinary medicine
  • These compositions may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients
  • the adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents
  • the compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavorings, colorings, or stabilizers in order to obtain pharmaceutically acceptable preparations
  • excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets
  • lactose and high molecular weight polyethylene glycols When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used
  • compositions containing the compounds of the invention may be prepared by conventional means
  • compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebulizer or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler
  • Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of formulae (IA-F)
  • the percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained Obviously, several unit dosage forms may be administered at about the same time
  • the dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient In the adult, the doses are generally from about 0 01 to about 100, preferably about 0 01 to about 10, mg/kg body weight per day by inhalation, from about 0 01 to about 100, preferably 0 1 to 70, more especially 0 5 to 10, mg/kg body weight per day by oral administration, and from about 0 01 to about 50, preferably 0 01 to 10, mg/kg body weight per day by intravenous administration In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated
  • the products according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient Generally, the active product may be administered orally 1 to 4 times per day It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day
  • the present invention provides compounds which inhibit synaptic norepinephrine, dopamine and serotonin uptake and are therefore believed to be useful in treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine
  • the compounds of the formulae (IA-F) inhibit synaptic norepinephrine, dopamine and serotonin uptake, in any individual compound these inhibitory effects may be manifested at the same or vastly different concentrations or doses
  • some compounds of the formulae (IA-F) are useful in treating such a disorder at doses at which synaptic norepinephrine uptake may be substantially inhibited but at which synaptic serotonin uptake or dopamine uptake is not substantially inhibited, or visa versa
  • some compounds of the formulae (IA-F) are useful in treating such a disorder at doses at which synaptic dopamine uptake may be substantially inhibited but at which synaptic norepin
  • concentrations or doses at which a test compound inhibits synaptic norepinephrine, dopamine and serotonin uptake is readily determined by the use of standard assay and techniques well known and appreciated by one of ordinary skill in the art
  • the degree of inhibition at a particular dose in rats can be determined by the method of Dudley, et al , J Pharmacol Exp Ther 217, 834-840 (1981 ), which is incorporated by reference
  • the therapeutically effective inhibitory dose is one that is effective in substantially inhibiting synaptic norepinephrine uptake, synaptic dopamine uptake, or synaptic serotonin uptake or inhibiting the synaptic uptake of two or more of norepinephrine, dopamine and serotonin uptake
  • the therapeutically effective inhibitory dose can be readily determined by those skilled in the art by using conventional range finding techniques and analagous results obtained in the test systems described above.
  • Compounds of this invention provide a particularly beneficial therapeutic index relative to other compounds available for the treatment of similar disorders. Without intending to be limited by theory, it is believed that this is due, at least in part, to some of the compounds' having higher binding affinities, e.g. their ability to be selective, for the norepinephrine transporter protein ("NET") over the transporters for other neurochemicals, e.g., the dopamine transporter protein (“DAT”) and the serotonin transporter protein (“SERT”).
  • NET norepinephrine transporter protein
  • DAT dopamine transporter protein
  • SERT serotonin transporter protein
  • Binding affinities are demonstrated by a number of means well known to ordinarily skilled artisans, including, without limitation, those described in the Examples section hereinbelow. Briefly, for example, protein-containing extracts from cells, e.g., HEK293E cells, expressing the transporter proteins are incubated with radiolabelled ligands for the proteins. The binding of the radioligands to the proteins is reversible in the presence of other protein ligands, e.g., the compounds of this invention; said reversability, as described below, provides a means of measuring the compounds' binding affinities for the proteins (Ki). A higher Ki value for a compound is indicative that the compound has less binding affinity for a protein than is so for a compound with a lower Ki; conversely, lower Ki values are indicative of greater binding affinities.
  • the difference in compound selectivity for proteins is indicated by a lower Ki for the protein for which the compound is more selective, and a higher Ki for the protein for which the compound is less selective.
  • the higher the ratio in Ki values of a compound for protein A over protein B the greater is the compounds' selectivity for the latter over the former (the former having a higher Ki and the latter a lower Ki for that compound).
  • Compounds provided herein induce fewer side effects during therapeutic usage because of their selectivity for the norepinephrine transporter protein, as indicated by the ratios of their Ki's for binding to NET over those for binding to other transporter proteins, e.g., DAT and SERT.
  • some of the compounds of this invention have a Ki ratio for DAT/NET of at least about 2: 1 ; generally also have a SERT/NET ratio of at least about 20: 1.
  • tetrabenazine (TBZ) (see, e.g., G. Stille, Arzn. Forsch 14:534-537, 1964. the contents of which are incorporated herein by reference). Randomized and coded doses of test compounds are administered to mice, as is then a dose of tetrabenazine. Animals are then evaluated for antagonism of tetrabenazine-induced exploratory loss and ptosis at specified time intervals after drug administration.
  • TTZ tetrabenazine
  • Exploratory activity is, for example, evaluated by placing the animal in the center of a circle and then evaluating the amount of time it takes for the animal to intersect the circle's perimeter - generally, the longer it takes for the animal to make this intersection, the greater is its loss of exploratory activity. Furthermore, an animal is considered to have ptosis if its eyelids are at least 50% closed. Greater than 95% of the control (vehicle-treated) mice are expected to exhibit exploratory loss and ptosis; compound-related activity is then calculated as the percentage of mice failing to respond to the tetrabenazine challenge dose, with therapeutically more effective compounds expected to better at reducing loss of exploratory behavior and ptosis.
  • this invention provides methods of treating subjects afflicted with various neurological and psychiatric disorders by administering to said subjects a dose of a pharmaceutical composition provided herein.
  • Said disorders include, without limitation, attention deficit-hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, feeding disorders, obsessive compulsive disorder, analgesia, smoking cessation, panic attacks, Parkinson's and phobia.
  • the compounds provided herein are particularly useful in the treatment of these and other disorders due, at least in part, to their ability to selectively bind to the transporter proteins for certain neurochemicals with a greater affinity than to the transporter proteins for other neurochemicals.
  • Step A A solution of m-tolualdehyde (500 mg, 4.16 mmol), -(methylaminomethyl)benzyl alcohol (630 mg, 4.16 mmol) and acetic acid (0.5 ml) was stirred in methanol (16 ml) at 0°C under nitrogen as sodium cyanoborohydride (784 mg, 12.5 mmol) was added in small portions. The reaction mixture was stirred for 5 minutes at 0°C and two days at ambient temperature. The reaction mixture was brought to pH 12 with 2N sodium hydroxide, diluted with water, and extracted with diethyl ether (3X).
  • Step B The product from Step A (1.24 g, 4.90 mmol) was stirred in methylene chloride (208 ml) and treated dropwise with concentrated sulfuric acid (98%, 10 ml) over 3 minutes. After stirring for 20 minutes, the reaction was diluted with ice chips and made basic with 25% aqueous ammonium hydroxide. The reaction mixture was extracted with methylene chloride (3X) and the organic extracts combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
  • Step B The product from Step A (1.0 g, 4.0 mmol) was stirred in methylene chloride (100 ml) and treated dropwise with concentrated sulfuric acid (98%, 7.0 ml) over 3 minutes. After stirring for 1 hour, the reaction was diluted with ice chips and and made basic with 25% aqueous ammonium hydroxide. The reactions mixture was extracted with methylene chloride (3 X 100 ml) and the organic extracts combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
  • Step C The product from Step B was subjected to chiral HPLC separation employing a Chiral
  • the reaction was stirred 20 minutes and treated with sodium borohydride (0.64 g, 33.0 mmol) portionwise.
  • the reaction was stirred 1 hour and treated with 4'-fluoro-3'-methyl-2-bromoacetophenone (7.69 g, 33.0 mmol) followed by stirring for 45 minutes at room temperature.
  • the reaction was finally treated with sodium borohydride (1.0 g, 33 mmol) portionwise and stirring continued overnight.
  • the reaction was diluted with water (100 ml) and extracted with methylene chloride (3 X 100 ml). The combined organic extracts were washed with brine and dried over anhydrous sodium sulfate, followed by filtration and concentration in vacuo.
  • Step B The product from Step A (0.52 g, 2.0 mmol) was dissolved in methylene chloride (20 ml) and treated dropwise with concentrated sulfuric acid (98%, 3 ml). The reaction was stirred overnight at room temperature, then diluted with ice chips and and made basic with 25% aqueous ammonium hydroxide. The reaction mixture was extracted with methylene chloride (3 X 50 ml) and the organic extracts combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
  • Step A A solution of -(methylaminomethyl)benzyl alcohol (745 mg, 4.9 mmol) and triethylamine (0.79 ml, 5.66 mmol) in acetonitrile (45 ml) at 0°C under nitrogen was treated dropwise with 2-fluoro-3-methylbenzyl bromide ( 1.0 g, 4.9 mmol) as a solution in acetonitrile (25 ml). The reaction was stirred at 0°C for 1 hour and at room temperature for 1.5 hours, followed by dilution with water and extraction with methylene chloride (3X).
  • Step B The product from Step A (0.5 g, 1.8 mmol) was treated with sulfuric acid (3.7 ml) and purified by column chromatography as described for Example 1. Step B to afford the desired product
  • Step A Methylmagnesium bromide was added dropwise over 5 minutes to a stirred solution of
  • Step B The product from Step A (9.0 g, 52.0 mmol) in anyhdrous methylene chloride (60 ml) under nitrogen was added by cannula to a stirred suspension of pyridinium chlorochromate ( 16.7 g, 77.0 mmol) and diatomaceous earth ( 15 g) in anhydrous methylene chloride ( 150 ml) at 0°C under nitrogen. After stirring for 26 hours, the heterogeneous mixture was diluted with diethyl ether (300 ml), stirred for 1 hour, and filtered.
  • Step C The product from Step B (52 mmol) was treated with tetrabutylammonium tribromide
  • Step D Methylamine (40 wt% aqueous, 18.0 mmol) was added to a stirred solution of benzaldehyde (1.8 g, 17 mmol) in methanol (20 ml) under nitrogen. After stirring 10 minutes at room temperature, the solution was cooled to 0°C and treated with sodium borohydride (0.32 g, 8.5 mmol) portionwise. The reaction was stirred for 15 minutes, warmed to room temperature and stirred an additional 1 hour, whereupon the product from Step C (4.3 g, 17 mmol) was added.
  • Step E The product from Step D (1.77 g, 6.0 mmol) was stirred in concentrated sulfuric acid
  • Step F The product from Step E (1.7 g, 6.0 mmol) was treated with ethereal HCl (1.0 M, 12.0 ml, 12.0 mmol) in methanol (20 ml) to afford a precipitate.
  • Step G The product from Step E was subjected to chiral HPLC separation employing a Chiral
  • the reaction was stirred at room temperature for 1 hour and concentrated in vacuo to remove acetic acid.
  • Step B The product from Step A (37.0 g, 158.0 mmol) was dissolved in methylene chloride (290 ml) and added dropwise to a solution of N-benzyl-N-methylamine (20.3 ml, 158.0 mmol) and triethylamine (22.0 ml, 158.0 mmol) in methylene chloride (312 ml). The addition was carried out over 45 minutes at 0°C, warmed to room temperature and allowed to stir an additional 4 hours. The reaction was diluted with water (300 ml) and extracted with methylene chloride. The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
  • Step C The product from Step B (15.0 g, 54.0 mmol) was dissolved in methanol (65 ml), chilled in an ice bath and treated with sodium borohydride (1.38 g, 36.0 mmol). The reaction was stirred at 0°C for 1 hour and at room temperature for 1 hour, followed by quenching with water and extraction with methylene chloride. The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to directly provide the pure benzylic alcohol ( 14.4 g) as a yellow oil: ⁇ NMR
  • Step D The product from Step C (14.4 g, 52.0 mmol) was stirred in concentrated sulfuric acid (27.0 ml) and methylene chloride (333 ml) for 15 minutes at room temperature. The reaction was poured on ice, made alkaline with concentrated ammonium hydroxide, and extracted with diethyl ether.
  • Step F The product from Step D was subjected to chiral HPLC separation employing a Chiral
  • Step B To the product mixture from Step A (3.5 g, 14.7 mmol) and N-methyl-N-benzylamine (1.8 g, 14.7 mmol) in methylene chloride ( 15 ml) was added diisopropyl ethyl amine (3.0 ml. 17 mmol). The reaction was stirred at room temperature for 5.5 hours, then washed with water and dried over anhydrous sodium sulfate. After filtration and concentration in vacuo, the material was purified by column chromatography on silica gel (140 g) eluting with hexanes / ethyl acetate / triethylamine
  • Step C The product from Step B (1.1 g, 4.0 mmol) was dissolved in methanol, chilled in an ice bath and treated with sodium borohydride (0.1 g, 2.7 mmol). The reaction was stirred at 0°C for 1 hour and at room temperature for 1 hour, followed by quenching with water and extraction with methylene chloride. The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to provide the benzylic alcohol (0.8 g) as an orange oil: ] H NMR (300 MHz, CDCI3) ⁇ 7.40-7.30
  • Step D The product from Step C (0.4 g, 1.4 mmol) was stirred in concentrated sulfuric acid (1.5 ml) and methylene chloride ( 10 ml) for 15 minutes at room temperature. The reaction was poured on ice, made alkaline with concentrated ammonium hydroxide, and extracted with diethyl ether. The combined ether extracts were dried over sodium sulfate, filtered and concentrated in vacuo. Purification by column chromatography on silica gel (15 g) eluting with hexanes / ethyl acetate / triethylamine
  • Step A Nitromethane ( 1.6 L, 30 mmol) was added dropwise to an ice-cold solution of tetrabutylammonium fluoride (7.5 mmol) in dry THF (20 mL). A solution of 3,5-difluorobenzaldehyde (2.85 g, 20.1 mmol ) in dry THF (5 L) was added dropwise. Triethylamine (2.8 mL, 20 mmol) was then added dropwise. A solution of terf-butyldimethylsilyl chloride (4.54 g, 30.1 mmol) in dry THF (15 mL) was added dropwise, causing a white precipitate to form.
  • Step B A slurry of the product from Step A (2.35 g, 1 1.6 mmol) and platinum oxide (0.20 g) in absolute ethanol (20 mL) was hydrogenated at 40 psig for 4 h. The reaction was filtered throgh a plug of Celite, which was washed with additional absolute ethanol.
  • Step C A solution of 3-methylacetophenone (1.36 g, 10.1 mmol) and the product from Step B
  • Step D Concentrated H,S0 4 (12.0 mL) was added to a stirred, ice-cold solution of the crude product from Step C (3.00 g, 10.3 mmol) in CH 2 C1 2 (105 mL). After stirring 15 min, the mixture was poured onto ice, made strongly alkaline with excess cone. NH 4 OH, and extracted (2 x) with Et,0. The combined organic extracts were dried over Na,S0 4 , filtered, and the solvent was removed in vacuo.
  • Step E Formaldehyde (37 wt%, 0.70 mL, 9.4 mmol) was added to a solution of the product from Step D (426 mg, 1.56 mmol) in methanol ( 16 mL). After 1.5 h, Raney nickel (0.51 g) was added. and the reaction was hydrogenated at 35 psig for 21 h. The reaction was filtered through a pad of Celite, which was washed with methanol. The filtrate was evaporated in vacuo, leaving a milky liquid, which was extracted with ether. The ether extract was dried over Na 2 S0 4 , filtered, and the solvent was removed in vacuo.
  • Step F A 1 M HCl solution in ether (1.0 mL, 1.0 mmol) was added dropwise to a stirred solution of of the product from Step E (82 mg, 0.28 mmol) in methanol (3 mL). After 30 min, the solvents and excess HCl were removed in vacuo. and the residue precipitated from ether and sonicated for 30 min.
  • Step B Triethylamine (8.40 mL, 60.0 mmol) was added to a stirred solution of the product from Step A (8.35 g, 60.0 mmol) and phenacyl bromide ( 1 1.94 g, 60.0 mmol) in CH : C1 2 (200 L) at room temperature under N vide.
  • Step C Sodium borohydride (4.54 g, 120 mmol) was added portionwise to a stirred solution of the product from Step B (17.1 g, -60.0 mmol) in MeOH (150 mL), cooled to 0 °C under N 2 . After stirring for 4.5 h at room temperature, the reaction was diluted with H 2 0 (300 mL) and extracted (4 x) with CH 2 C1 2 . The organic extracts were combined, washed with sat. NaCl, dried over Na 2 S0 4 , filtered, and the solvent evaporated in vacuo.
  • Step D Cone, sulfuric acid (24 mL) was added dropwise to a stirred solution of the product from Step C (14.8 g, 57.1 mmol) in CH,C1 2 (280 mL), cooled to 0 °C, using an ice-water bath. The cooling bath was removed after addition was complete and the reaction was vigorously stirred at room temperature for 20 min. The reaction was then poured into an ice / water mixture (400 mL) and the resultant mixture basified with cone. NH OH solution to pH ⁇ 10. The aq. layer was extracted (3 x) with CH 2 C1 The organic extracts were combined, washed with a 2: 1 mixture of sat.
  • Step E r-Butyl lithium (30 mL, 1.7 M in pentane, 50.5 mmol) was added dropwise to a stirred solution of the product from Step D (5.50 g, 22.8 mmol) and TMEDA (7.6 mL, 50.2 mmol) in Et 2 0 (120 mL) cooled to -60 °C under N,. After stirring for 45 min, DMF (7.0 mL, 91.2 mmol) was added and the reaction mixture was stirred at -60 °C for 1.5 h.
  • DMF 7.0 mL, 91.2 mmol
  • Step G An ethereal HCl solution (1.80 mL, 1 N, 1.80 mmol) was added to a solution of the product from Step F (0.10 g, 0.35 mmol) in MeOH (0.5 mL) and Et 2 0 (5 mL) at room temperature, resulting in the formation of a off-white solid.
  • Step A Methylamine (40 wt% aqueous, 2.6 mL. 30 mmol) was added to a stirred solution of 3- bromobenzaldehyde (5.44 g, 29.4 mmol) in MeOH (30 mL) under N,. After stirring 1 h, the colorless solution was cooled to 0 °C and then NaBH (0.60 g, 16 mmol) was added portionwise. After stirring 1 h, the cooling bath was removed. After stirring for 90 min, the reaction was cooled to 0 °C and then phenacyl bromide (5.90 g, 29.6 mmol) was added portionwise over 30 min. The reaction was allowed to warm to room temperature.
  • Step B Cone. H 2 S0 (40.0 mL) was added dropwise over 15 min to a stirred solution of the product from Step A (9.18 g, 28.7 mmol) in CH,C1 2 (300 mL). After stirring 45 min, the mixture was poured onto ice, made strongly alkaline with excess cone. NH 4 OH, extracted (3 x) with Et 2 0.
  • Step C A slurry of bromide the product from Step B (1.15 g, 3.81 mmol), zinc cyanide (271 mg, 2.31 mmol) , and tetrakis(triphenylphosphine)palladium(0) (266 mg, 0.230 mmol) in dry DMF (5 mL) was heated at 83 °C for 24 h. After allowing the reaction to cool to room temperature, the reaction was diluted with toluene and washed with 2 N NaOH. The toluene extract was dried over Na,S0 4 , filtered, and concentrated in vacuo.
  • Step D A solution of the product from Step C (201 mg, 0.809 mmol) in dry THF (4 mL) was added dropwise to an ice-cold slurry of lithium aluminum hydride (61 mg, 1.6 mmol) in dry THF (2 mL). The reaction was stirred for 90 min with cooling and then was allowed to warm to room temperature. The reaction was stirred for 5 h and then was quenched with EtOAc and then a saturated Na,S0 4 solution. The reaction was diluted with ether, dried over solid Na,S0 4 , filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (26 g) eluting with 12% methanol/chloroform containing 1 % cone.
  • Step E A slurry of the product from Step D (53 mg. 0.21 mmol) and maleic acid (25 mg, 0.22 mmol) in absolute EtOH (10 mL) was heated in a 40 °C water bath until all of the solid had dissolved. After 1 h, the reaction was concentrated in vacuo. The residue was recrystallized from ethanol/ether producing the bis maleate salt (43 mg, 42%) as a green solid: mp 176-177 °C (with decomposition); ⁇ NMR (300 MHz.
  • Step A A 1 M HCl solution in ether (3.0 mL, 3.0 mmol) was added dropwise to a solution of the product from Step C, Example 90 (82 mg, 0.32 mmol) in methanol (6 mL). The solvents and excess HCl were removed in vacuo leaving a green solid. A slurry of this green solid, potassium carbonate (199 mg, 1.44 mmol), and ethyl chloroformate (0.20 mL, 2.1 mmol) in methanol (1 mL) and acetone (6 mL) was heated at 50 °C for 20 h.
  • Step C A slurry of the product from Step B (20 mg, 0.075 mmol) and maleic acid (9 mg, 0.08 mmol) in absolute EtOH (5 mL) was heated in a 40 °C water bath until all of the solid had dissolved. After 2 h. the reaction was concentrated in vacuo. The residue was recrystallized from ethanol/ether producing the bis maleate product ( 13 mg, 35%) as a tan solid: mp 160- 163 °C (with decomposition); ⁇ NMR (300 MHz, CDOD) ⁇ 7.41-7.31 (m, 5H), 7.24-7.21 (m. 2H), 6.99 (d.
  • Step A A solution of /V-methyl-2-methoxy amine (8.00 g, 52.9 mmol) and triethylamine (5.40 g, 53.0 mmol) in dichloromethane ( 100 mL) was cooled in an ice water bath. The 2-bromoacetophenone (10.5 g, 53.0 mmol) was added, and the reaction was allowed to warm to room temperature. The reaction mixture was diluted with water (200 mL) and MTBE (200 mL). Layers were separated, and the organic layer was washed with H 2 0 and brine.
  • Step B The product from Step A (12.6 g, 46.8 mmol) was taken up in methanol (120 mL) and cooled in an ice- water bath. Sodium borohydride (1.76 g, 46.8 mmol) was added portionwise. The reaction was stirred for 1 h at ambient temperature. The reaction mixture was concentrated to half of the original volume. Water (100 mL) was added, and the mixture was extracted (3 x) with dichloromethane.
  • Step C Methanesulfonic acid (47.7 mL, 735 mmol) was added at ambient temperature to a solution of the product from Step B (4.20 g, 13.7 mmol) in dichloromethane (250 mL). The reaction mixture was stirred at room temperature under nitrogen for 24 h. After the reaction was complete, the reaction was made basic (pH - 1 1 ) with 2 N NaOH, and extracted (3 x) with methylene chloride. The combined organic layers were washed with brine, dried over MgS0 and concentrated in vacuo.
  • Step D A solution of the product from Step C (5.60 g, 22.1 mmol) in 48% hydrobromic acid (60 mL) was refluxed at 100 °C for 3 h. The reaction mixture was concentrated in vacuo and recrystallized from ethanol to yield the desired product (4.74 g, 67): ⁇ NMR (300 MHz, DMSO-cQ ⁇ 9.92 (s, IH), 7.48-7.25 (m, 3H), 7.21 (d.
  • Step F The product from Step E (1.00 g, 2.87 mmol) was dissolved in water (20 mL) before treatment with sodium sulfate (100 mg) and hydroxyl amine sulfonate (0.32 mg 2.87 mmol). Reaction was stirred for 2 h. Reaction was cooled in an ice- water bath and treated with CH 2 C1 2 (20 mL). Sodium bicarbonate (600 mg) was added and the reaction was allowed to warm to ambient temperature. The solids were filtered off and combined with the organic layer. The mixture was concentrated and chromatographed (SiO cleanOAc/hexanes, 1/1). Two compounds eluted simultaneously. The mixture was treated with ethanol (5 mL) and filtered.
  • Step A A solution of Step C, Example 90 (127 mg, 0.51 1 mmol) in dry toluene (13 mL) was cooled to -16 °C and then 1 M DIBAL-H in toluene ( 1.7 mL, 1.7 mmol) was added dropwise. The reaction was stirred for 45 min with cooling and then EtOAc (1.1 L) was added. The reaction was allowed to warm to room temperature. The reaction was stirred for 45 min and then 1 N H 2 S0 4 ( 12 mL) was added. The reaction was heated at reflux for 30 min. After allowing the reaction to cool to room temperature, the reaction was diluted with water, made basic with 2 N NaOH, and extracted (2 x) with CH,C1,.
  • Step B To an ice-cold solution of the product from Step A (1 10 mg. 0.438 mmol) in methanol (20 mL) was added NaBH 4 (36 mg, 0.95 mmol). The reaction was slowly allowed to warm to room temperature overnight. The reaction was quenched with water and brine and then was extracted (3 x) with CH,CL. The combined organic extracts were dried over Na,S0 4 , filtered, and concentrated under reduced pressure. The residue (106 mg) was purified by column chromatography on silica gel (31 g) eluting with EtOAc to give the desired alcohol (44 mg, 40%) as a yellow oil: ⁇ NMR (300 MHz. CDC1,) ⁇ 7.32-7.22 (m. 3H).
  • Step A Ethylene glycol dimethyl ether (20 mL) and 2 N Na 2 CO, (12.2 mL) were sparged with N 2 and charged to a round bottom flask containing 4-bromoisoquinoline (2 g, 9.6 mmol), phenylboronic acid (1.76 g, 14.4 mmol), and Pd(PPh,) 4 (1.1 1 g, 0.96 mmol). The entire solution was sparged with N 2 . The resulting reaction mixture was heated to reflux under N, overnight. The solution was cooled, quenched with saturated NaHCO, (230 mL), and extracted five times with ethyl ether.
  • Step B Ethyl triflate (383 mg, 2.15 mmol) was added dropwise to a solution of the product from Step A (400 mg, 1.95 mmol) in CH,C1, (24 mL) at 0"C under N literature. The solution was stirred for 15 min. at room temperature. The solvent was removed in vacuo to yield the triflate salt of the isoquinoline as a white solid (420 mg, 56% yield).
  • the triflate salt (420 mg. 1.09 mmol) was dissolved in MeOH ( 16 mL), and NaCNBH, ( 159 mg, 2.53 mmol) was added to the solution. The resulting reaction mixture was stirred for 5 min., and a few drops of bromocresol green in MeOH were added.
  • Binding Assays P ⁇ marv binding assays
  • HEK293E cell lines were developed to express each of the three human transporters cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries
  • the cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstem-Barr virus based expression plasmid (E Shen, GM Cooke, RA Horhck, Gene 156.235-239, 1995)
  • This plasmid containing the coding sequence for one of the human transporters was transfected into HEK293E cells Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of t ⁇ tiated NE, DA or 5HT
  • mice Male CFI mice (Charles River Breeding Laboratories) weighing 18-25 gm at the time of testing, are housed a minimum of06 days under carefully controlled environmental conditions (22 2 + 1 1 C, 50% average humidity, 12 hr lighting cycle/24 hr) Mice are fasted overnight ( 16-22 hr) prior to testing Mice are placed into clear polycarbonated "shoe" boxes (17 cm x 28 5 cm x 12 cm) Randomized and coded doses of test compounds are administered p o A 45 mg/kg dose of tetrabenazine is administered I p 30 minutes prior to score time All compounds are administered in a volume of 0 1 ml/10 gm body weight Animals are evaluated for antagonism of tetrabena
  • mice are examined for signs of exploratory activity and ptosis.
  • Exploratory activity is evaluated by placing the animal in the center of a 5 inch circle. Fifteen seconds are allowed for the animal to move and intersect the perimeter. This is considered antagonism of tetrabenazine and given a score of 0. Failure to leave the circle is regarded as exploratory loss and given a score of 4. An animal is considered to have ptosis if its eyelids are at least 50% closed and given a score of 4 if completely closed. No closure is given a score of 0. Greater than 95% of the control (vehicle-treated) mice are expected to exhibit exploratory loss and ptosis. Drug activity is calculated as the percentage of mice failing to respond to the tetrabenazine challenge dose.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

On décrit des composés de formules IA-IF. Ces composés sont des tétrahydroisoquinolines de structure (A) dans laquelle R1-R8 pour des composés représentés par chacune des formules IA, IB, IC, ID, IE et IF sont tels que décrits dans le descriptif. Ces composés sont tout particulièrement utiles dans le traitement de divers troubles neurologiques et psychiatriques, par exemple, le trouble d'hyperactivité avec déficit de l'attention (THADA).
EP00976884A 1999-11-03 2000-11-03 Tetrahydroisoquinolines a substitution 4-phenyle et utilisation de ces dernieres pour bloquer le recaptage de la norepinephrine, de la dopamine et de la serotonine Withdrawn EP1246805A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16327099P 1999-11-03 1999-11-03
US163270P 1999-11-03
PCT/US2000/030328 WO2001032624A1 (fr) 1999-11-03 2000-11-03 Tetrahydroisoquinolines a substitution 4-phenyle et utilisation de ces dernieres pour bloquer le recaptage de la norepinephrine, de la dopamine et de la serotonine

Publications (1)

Publication Number Publication Date
EP1246805A1 true EP1246805A1 (fr) 2002-10-09

Family

ID=22589231

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00976884A Withdrawn EP1246805A1 (fr) 1999-11-03 2000-11-03 Tetrahydroisoquinolines a substitution 4-phenyle et utilisation de ces dernieres pour bloquer le recaptage de la norepinephrine, de la dopamine et de la serotonine

Country Status (11)

Country Link
EP (1) EP1246805A1 (fr)
JP (1) JP4907817B2 (fr)
KR (2) KR100878855B1 (fr)
CN (1) CN100436420C (fr)
AU (1) AU784280B2 (fr)
BR (1) BR0015307A (fr)
CA (1) CA2389300C (fr)
MX (1) MXPA02004329A (fr)
NZ (1) NZ519146A (fr)
RU (1) RU2293728C2 (fr)
WO (1) WO2001032624A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
RU2309953C2 (ru) * 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
WO2002059074A1 (fr) 2001-01-26 2002-08-01 Sankyo Company, Limited Analogue de benzylamine
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
DE10154689A1 (de) * 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
ATE425968T1 (de) * 2001-12-05 2009-04-15 Sanofi Aventis Deutschland Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
MXPA05005586A (es) * 2002-12-02 2005-07-27 Pharmacia & Up John Company Ll El uso de tetrahidroisoquinolinas 4-fenilsustituidas en el tratamiento del dolor, migrana e incontinencia urinaria.
WO2004050630A1 (fr) * 2002-12-02 2004-06-17 Pharmacia & Upjohn Company Llc Utilisation de tetrahydroisoquinoleines a substitution dans le traitement de douleurs chroniques et neuropathiques, de cephalee migraineuse et de l'incontinence urinaire par imperiosite, d'effort et mixte
JP2006509782A (ja) * 2002-12-02 2006-03-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疼痛、片頭痛および尿失禁の治療における４−フェニル−置換テトラヒドロイソキノリンの使用
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DK2206496T3 (da) 2003-05-05 2014-12-15 Probiodrug Ag Screening af inhibitorer af pyroglutaminsyredannelse i amyloid beta-peptid
JP5707014B2 (ja) 2003-10-15 2015-04-22 プロビオドルグ エージー グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用
GEP20094640B (en) * 2004-07-15 2009-03-10 Bristol Myers Squibb Co Aryl-and heteroaryl-substituted tetrahydro isoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US20060111394A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
WO2006066197A1 (fr) * 2004-12-17 2006-06-22 Janssen Pharmaceutica, N.V. Composes de tetrahydroisoquinoline pour le traitement de troubles du systeme nerveux central
DE102005001411A1 (de) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
FR2884251B1 (fr) * 2005-04-08 2007-07-13 Servier Lab Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE602006002894D1 (de) 2005-06-17 2008-11-06 Janssen Pharmaceutica Nv Naphthyridinverbindungen
US7754882B2 (en) 2005-06-17 2010-07-13 Janssen Pharmaceutica Nv Hexahydro-pyrrolo-isoquinoline compounds
EP1904069B1 (fr) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
CN101258130B (zh) * 2005-09-09 2012-11-28 阿纳里特康股份有限公司 作为胰岛素样生长因子-1受体抑制剂的异喹啉
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
CN100386319C (zh) * 2005-12-05 2008-05-07 中国人民解放军第二军医大学 具有抗生育和抗真菌活性的四氢异喹啉类化合物或其盐类
JP2009538857A (ja) * 2006-05-31 2009-11-12 エフ．ホフマン−ラ ロシュ アーゲー モノアミン再取り込み阻害薬としてのベンゾアゼピン誘導体
US7846930B2 (en) 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2429295B1 (fr) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation
MX2011011907A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2, 3,4-tetrahidroisoquinolina y uso de la misma.
WO2010132487A1 (fr) * 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
EP2420237A1 (fr) * 2010-08-11 2012-02-22 Ville Takio Dérivés fluorés d'isoquinoléines endogènes pour leur utilisation dans le traitement de maladies liées aux passages d'isoquinoline endogène

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947456A (en) * 1970-01-06 1976-03-30 Hoffman-La Roche Inc. Substituted 4-phenyl isoquinolines
CH527194A (de) * 1970-01-06 1972-08-31 Hoffmann La Roche Verfahren zur Herstellung von Isochinolin-Derivaten
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
GB1504424A (en) * 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
BG49761A1 (en) * 1989-04-24 1992-02-14 Vissh Khim T I 4- (4'- chalophenyl)- 2- methyl- 1, 2, 3, 4- tetrahydroisohinolines and method for its preparation
US5607939A (en) * 1994-04-28 1997-03-04 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
RU2309953C2 (ru) * 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0132624A1 *

Also Published As

Publication number Publication date
CA2389300C (fr) 2010-06-08
MXPA02004329A (es) 2005-08-26
RU2293728C2 (ru) 2007-02-20
KR20020081211A (ko) 2002-10-26
KR100878855B1 (ko) 2009-01-15
AU784280B2 (en) 2006-03-02
KR20080065707A (ko) 2008-07-14
JP4907817B2 (ja) 2012-04-04
CN1413197A (zh) 2003-04-23
NZ519146A (en) 2004-02-27
BR0015307A (pt) 2002-07-09
AU1459601A (en) 2001-05-14
CN100436420C (zh) 2008-11-26
JP2004501860A (ja) 2004-01-22
CA2389300A1 (fr) 2001-05-10
WO2001032624A1 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
CA2389300C (fr) Tetrahydroisoquinolines a substitution 4-phenyle et utilisation de ces dernieres pour bloquer le recaptage de la norepinephrine, de la dopamine et de la serotonine
US20060111396A1 (en) 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7612090B2 (en) Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
AU2005274927B2 (en) Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20060111395A1 (en) Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US9604960B2 (en) Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US7163949B1 (en) 4-phenyl substituted tetrahydroisoquinolines and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: LT;LV;RO;SI

17Q First examination report despatched

Effective date: 20040126

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMR TECHNOLOGY, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120320